American Family Physician - Amlodipine/atorvastatin for preventing heart disease
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c49672) has announced the addition of The Cardiovascular Market Outlook to 2011 to their offering.
The Cardiovascular Market Outlook to 2011 is a new report from Business Insights providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market.
Most Popular
Today’s Best Part-Time Jobs
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
Five Ways To Successfully Negotiate A Salary
Eight Major Job Trends For 2008
This report offers insight into R&D trends in the cardiovascular market, including the discontinuation of key pipeline drugs such as Pfizer’s torcetrapib and atorvastatin, and the development of new drug classes including Novartis’ Rasilez (aliskiren), anticipated to be the first to market direct renin inhibitor.
Use this report to identify the leading cardiovascular companies to 2011 and discover the cardiovascular blockbusters of the future.
Key findings of the report…
-Anti-hypertensives have been the highest selling portion of the cardiovascular market in 2005. Norvasc was the leading anti-hypertensive drug in 2005, with sales of $5bn, an increase of 3.9% from 2004.
-In 2006 the patents protecting Zocor and Pravachol expired, which together with the anticipated patent expiry of Lipitor in 2010, will result in a flood of generic statins onto the market, heavily impacting sales of branded drugs.
-Two key anti-hypertensives are forecast to launch in 2007: Novartis’ Rasilez (aliskiren) and Exforge (valsartan plus amlodipine). Exforge gained FDA approval in December 2006 and is predicted to generate high sales.
-Pfizer’s torcetrapib and atorvastatin was discontinued in late 2006 due to safety concerns. The discontinuation of torcetrapib will have an impact on the other members of the CETP inhibitor pipeline drugs, in particular Roche’s JTT-705.
-Pfizer is the leading global cardiovascular company, with sales of nearly $20bn in 2005, representing 15.6% of the cardiovascular market.
-The largest growth seen in the cardiovascular market is from Amgen at 17.4%, with sales in 2005 of $6.4bn.
Key questions answered in this report
-What were the key events in the global cardiovascular market in 2005-06?
-What are the drivers and resistors to growth for the key players in the market?
-How has the failure of key pipeline products expected to impact the global cardiovascular market?
-What strategies are the leading companies implementing to maximize sales and boost market share?
-When will generic competition impact the leading cardiovascular brands?
-Which new product launches are forecast to gain blockbuster status?
-What will the competitive landscape in hypertension, thrombosis, dyslipidemia and arrhythmia look like in 2011?
Top five reasons to order your copy today
-Gain up-to-date competitive intelligence across the cardiovascular area and understand the major issues affecting key pharmaceutical marketers.
-Understand which cardiovascular indications have the greatest potential for growth through the 6-year forecasts in anti-hypertensive, anti-dyslipidemic, anti-thrombosis and cardiac therapy drug classes.
-Assess your potential competitive position to the leading cardiovascular companies, through the report’s extensive pipeline insight and profiles of upcoming launches.
-Examine factors impacting pipeline drugs, such as clinical trial results, discontinued products and patient potentials.
-Identify the critical success factors for your company to succeed in the cardiovascular market, through examination of winning growth strategies used by the leading players.
Content Outline:
The Cardiovascular Market Outlook to
Executive Summary
Patient potential
Global cardiovascular market analysis
Analysis of potential future cardiovascular blockbusters
Leading players in the cardiovascular market
Chapter 1 Patient potential
Chapter 2 Global cardiovascular market
Chapter 3 Analysis of potential future
Chapter 4 Leading players in the cardiovascular market
Chapter 5 Appendix
IMS data
Index
List of Figures
List of Tables
Companies Mentioned:
-Pfizer’s
-Merck’s
-Sanofi-Aventis
-Novartis
-Bristol-Myers Squibb’s
For more information visit http://www.researchandmarkets.com/reports/c49672
Source: Business Insights
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
